Alpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis

作者：Yiming Zhao, Yongjian Wang, Han-Yu Lou, Lizhen Shan · 发表于：Oncotarget · 年份：2017 · DOI：10.18632/oncotarget.17515 · 被引用次数：34 · 研究领域：Metabolism, Diabetes, and Cancer、Pancreatic and Hepatic Oncology Research、Diabetes Treatment and Management

// Yiming Zhao 1,* , Yongjian Wang 1,* , Hanyu Lou 1 and Lizhen Shan 1 1 Department of Endocrinology and Metabolism, the Second Affiliated Hospital Zhejiang University College of Medicine, Hangzhou, Zhejiang, China * These authors have Contributed equally to this work Correspondence to: Yongjian Wang, email: // Keywords : alpha-glucosidase inhibitor, diabetes mellitus, cancer risk, meta-analysis, systematic review Received : January 25, 2017 Accepted : April 17, 2017 Published : April 28, 2017 Abstract Several studies have shown that anti-diabetic medications may modify the risk of cancer. We performed a systematic review and meta-analysis to evaluate the effect of alpha-glucosidase inhibitors (AGIs) on the risk of cancer in patients with diabetes mellitus. We conducted a systematic search of Medline, EMBASE, and Web of Science databases, up to September 30, 2016. Random-effects model was used to estimate the summary odds ratios (ORs) with 95% CI. Twenty-five studies (14 cohort, 7 case-control, and 4 randomized controlled trials) involving 1,285,433 patients with diabetes were included. Meta-analysis of observational studies showed that the use of AGIs was associated with a lower risk of developing cancer (OR = 0.86, 95% CI 0.78-0.96), especially gastrointestinal cancer (OR = 0.83, 95% CI 0.71-0.97). There was considerable heterogeneity across the studies introduced partly by the quality of included studies and adjustment for potential confounders. Meta-analysis of randomized...